An analysis of potential safety and tolerability issues associated with GLP-1 analogs found the risk of hypoglycemia, injection-site reactions, pancreatitis, neoplasms, and gallbladder events to be generally low [20]. This evidence concerns the gene GLP1R and pancreatitis.